CJC-1295 no DAC 5mg

CJC‑1295 (No DAC) is a research peptide analog of growth hormone‑releasing hormone (GHRH) designed to stimulate the body’s own growth hormone (GH) system — but without the long‑acting modification found in CJC‑1295 with DAC. It’s used in laboratory and experimental settings to study endocrine regulation, GH dynamics, metabolism, and related physiology. 

🧬 What It Is

• Type: Synthetic GHRH analog — essentially a lab‑designed peptide that mimics the first 29 amino acids of natural GHRH with some substitutions to improve stability.  
• No DAC: “No DAC” means no Drug Affinity Complex — the biochemical tag that extends the half‑life of the standard CJC‑1295 peptide by binding to serum albumin. Without DAC, the peptide circulates for a much shorter time.  
• Research status: Sold and labeled strictly for research use only; not approved by the FDA or similar regulators for therapeutic or dietary use in humans.  

⚙️ How It Works

🧠 Growth Hormone Axis Modulation

CJC‑1295 No DAC acts on the growth hormone‑releasing hormone receptor (GHRH‑R) in the anterior pituitary gland:

• It binds to GHRH receptors, triggering a cascade that increases cyclic AMP (cAMP) and stimulates GH release.  
• The released GH then signals the liver to produce insulin‑like growth factor‑1 (IGF‑1), a mediator of many GH effects.  

⏱️ Short Half‑Life & Pulsatility

• Without the DAC modification, CJC‑1295 has a short circulation time (on the order of tens of minutes to a few hours), clearing rapidly from the system.  
• Because of this, it produces discrete, pulsatile GH release when dosed repeatedly — mimicking the body’s natural GH burst pattern more closely than long‑acting versions.  

🧪 Why Researchers Use CJC‑1295 (No DAC)

In research contexts, the No DAC form is often preferred when investigators want to:

• Study physiological GH pulses and how they influence downstream biology.  
• Model natural endocrine rhythms rather than sustained elevation of GH.  
• Pair with other peptides like ghrelin receptor agonists (e.g., Ipamorelin) to explore GH regulatory pathways and synergistic effects.  

Because its half‑life is short, dosing in experimental models is frequent compared with long‑acting analogs.